A randomized, double-blind, controlled, small-sample pre-clinical trial of Yiqi Huoxue Powder in the treatment of sepsis

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000037831

Enrollment

Unknown

Registered

2020-09-02

Start date

2020-09-03

Completion date

Unknown

Last updated

2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Experimental group:On the basis of the western medicine intervention plan, the granules of Yiqi huoxue Powder (30g shengtan ginseng, 30g panax notoginseng, 5g rhubarb 5g/10g/15g, 1 dose per day, oral

Course of treatment: 7 days)

Control group:On the basis of western medicine intervention plan, placebo granule (30g shengtan ginseng placebo granule, 30g Sanqi placebo granule, 5g/10g/15g rhubarb placebo granule, 1 dose per day,

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients who met the diagnostic criteria of sepsis 3.0 in 2016; 2. Patients who met the diagnostic criteria of pneumonia, and the source of sepsis was pneumonia; 3. Patients aged 18-80 years old; 4. Patients with informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who may die within 24 hours; 2. Patients with serious condition and need cardiopulmonary resuscitation; 3. Patients with advanced malignant tumor with cachexia; 4. Patients with acute coronary artery disease, such as acute myocardial infarction; 5. The patients who are allergic to the prescription of Yiqi Huoxue powder or allergic constitution; 6. Pregnant women; 7. Patients who have participated in other clinical trials in recent 3 months. 8. There are other situations that the clinical researcher thinks is not suitable to participate in the study.

Design outcomes

Primary

Measure	Time frame
28-day case fatality rate;	—

Secondary

Measure	Time frame
7 day case fatality rate;Whether PICS occur;SOFA score;APACHE? score;Number of days without ventilator support;Length of stay in ICU;Hospitalization days;White blood cell count;procalcitonin;hs-CRP;T lymphocyte subsets;CD14+/HLA-DR;PD-1;PD-L1;	—

Countries

China

Contacts

Public ContactLi Jun

Guangdong Provincial Hospital of traditional Chinese Medicine

lijun1401@163.com+86 13728065350

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026